Fig. 1 | Mucosal Immunology

Fig. 1

From: A role for the CCR5–CCL5 interaction in the preferential migration of HSV-2-specific effector cells to the vaginal mucosa upon nasal immunization

Fig. 1

Intravaginal PTx treatment diminishes the number of HSV-2-specific IFN-γ-secreting cells in vaginal tissue after nasal immunization (n.i.). Each group of three mice was immunized with a single nasal dose of 105 PFU of HSV-2 TK− or PBS (nonimmunized group). For the PTx treatment, PTx (0.5 μg) was administered intravaginally for 4 consecutive days (days 3 through 6) after nasal immunization. On day 7, whole cells prepared from the vaginal tissues or spleens of the three mice in each group were pooled and stimulated by coincubation for 72 h in vitro with irradiated syngeneic splenocytes (as antigen-presenting cells) and heat-inactivated virus antigens, as shown in a. The absolute numbers of IFN-γ-secreting cells in the b vaginal tissues and c splenic tissue at 1 week after immunization were calculated by using ELISPOT assays. Values are means ± 1 SD (n = 3 per group). Data are representative of two independent experiments. **P < 0.01 versus nasally immunized (n.i.) mice

Back to article page